Pierluigi di Mauro
Overview
Explore the profile of Pierluigi di Mauro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pedersini R, Schivardi G, Lagana M, Laini L, di Mauro P, Zamparini M, et al.
Breast
. 2024 Sep;
78:103794.
PMID: 39265313
Purpose: The impact of dietary counseling on body composition in early breast cancer patients (EBC) treated with aromatase inhibitors (AIs) is uncertain. The aim of this study was to assess...
2.
Regorafenib-related erythrocytosis in metastatic extra-gastrointestinal stromal tumor: a case report
Fassi E, Amoroso V, Cosentini D, Ferrari V, Lagana M, Berruti A, et al.
Front Oncol
. 2024 Aug;
14:1398055.
PMID: 39165680
Introduction: Regorafenib is an oral multi-targeted tyrosine kinase inhibitor (TKI) indicated for the treatment of various tumor types, including metastatic gastrointestinal stromal tumors (GIST), as a third-line systemic therapy. Erythrocytosis,...
3.
Pedersini R, Buffoni M, Petrelli F, Ghidini A, di Mauro P, Amoroso V, et al.
Clin Breast Cancer
. 2024 May;
24(5):411-420.
PMID: 38734491
Trastuzumab emtansine (T-DM1), sacituzumab govitecan (SG), and trastuzumab deruxtecan (T-DXd) are three ADCs approved for the treatment of metastatic breast cancer (MBC). Since gastrointestinal toxicities have been commonly observed with...
4.
Cosentini D, Pedersini R, di Mauro P, Zamparini M, Schivardi G, Rinaudo L, et al.
JAMA Netw Open
. 2024 Jan;
7(1):e2350950.
PMID: 38198137
Importance: Women with early breast cancer (EBC) exposed to aromatase inhibitors (AIs) may experience fragility fractures despite treatment with bone-active drugs. Risk factors for fractures in patients receiving AIs and...
5.
Zattarin E, Mariani L, Menichetti A, Leporati R, Provenzano L, Ligorio F, et al.
Ther Adv Med Oncol
. 2023 Dec;
15:17588359231204857.
PMID: 38130467
Background: Cyclin-Dependent Kinase 4/6 inhibitors (CDK4/6i) combined with Endocrine Therapy (ET) are the standard treatment for patients with Hormone Receptor-positive/HER2-negative advanced breast cancer (HR+/HER2- aBC). Objectives: While CDK4/6i are known...
6.
Pedersini R, Lagana M, Bosio S, Zanini B, Cosentini D, di Mauro P, et al.
Breast Cancer Res Treat
. 2023 Sep;
202(3):461-471.
PMID: 37695400
Purpose: We aimed to investigate the role of a lifestyle intervention and clinical and therapeutic factors for preventing weight gain in early breast cancer (BC) patients from one week before...
7.
Dalla Volta A, Caramella I, di Mauro P, Bergamini M, Cosentini D, Valcamonico F, et al.
Curr Oncol Rep
. 2023 Aug;
25(10):1141-1152.
PMID: 37624550
Purpose Of Review: This review paper is intended to show that changes in body composition are key in the pathogenesis of bone fragility amongst patients with breast and prostate cancer...
8.
Zattarin E, Presti D, Mariani L, Sposetti C, Leporati R, Menichetti A, et al.
NPJ Breast Cancer
. 2023 Apr;
9(1):27.
PMID: 37069173
Whether Human Epidermal growth factor Receptor 2 (HER2)-low status has prognostic significance in HR + /HER2- advanced Breast Cancer (aBC) patients treated with first-line Endocrine Therapy plus CDK 4/6 inhibitors...
9.
di Mauro P, Schivardi G, Pedersini R, Laini L, Esposito A, Amoroso V, et al.
Front Oncol
. 2023 Mar;
13:1139372.
PMID: 36890829
Background: Triple-negative breast cancer (TNBC) is an aggressive cancer subtype, owing to its high metastatic potential: Patients who develop brain metastases (BMs) have a poor prognosis due to the lack...
10.
Pedersini R, Cosentini D, Rinaudo L, Zamparini M, Ulivieri F, di Mauro P, et al.
Bone Rep
. 2023 Jan;
18:101654.
PMID: 36700242
Background: Bone mineral density (BMD) lacks sensitivity in individual fracture risk assessment in early breast cancer (EBC) patients treated with aromatase inhibitors (AIs). New dual-energy X-ray absorptiometry (DXA) based risk...